Author: Ayeh, Samuel K.; Abbey, Enoch J.; Khalifa, Banda A. A.; Nudotor, Richard D.; Osei, Albert Danso; Chidambaram, Vignesh; Osuji, Ngozi; Khan, Samiha; Salia, Emmanuella L.; Oduwole, Modupe O.; Yusuf, Hasiya E.; Lasisi, Oluwatobi; Nosakhare, Esosa; Karakousis, Petros C.
Title: Statins use and COVID-19 outcomes in hospitalized patients Cord-id: reslqqlb Document date: 2021_9_10
ID: reslqqlb
Snippet: BACKGROUND: There is an urgent need for novel therapeutic strategies for reversing COVID-19-related lung inflammation. Recent evidence has demonstrated that the cholesterol-lowering agents, statins, are associated with reduced mortality in patients with various respiratory infections. We sought to investigate the relationship between statin use and COVID-19 disease severity in hospitalized patients. METHODS: A retrospective analysis of COVID-19 patients admitted to the Johns Hopkins Medical Inst
Document: BACKGROUND: There is an urgent need for novel therapeutic strategies for reversing COVID-19-related lung inflammation. Recent evidence has demonstrated that the cholesterol-lowering agents, statins, are associated with reduced mortality in patients with various respiratory infections. We sought to investigate the relationship between statin use and COVID-19 disease severity in hospitalized patients. METHODS: A retrospective analysis of COVID-19 patients admitted to the Johns Hopkins Medical Institutions between March 1, 2020 and June 30, 2020 was performed. The outcomes of interest were mortality and severe COVID-19 infection, as defined by prolonged hospital stay (≥ 7 days) and/ or invasive mechanical ventilation. Logistic regression, Cox proportional hazards regression and propensity score matching were used to obtain both univariable and multivariable associations between covariates and outcomes in addition to the average treatment effect of statin use. RESULTS: Of the 4,447 patients who met our inclusion criteria, 594 (13.4%) patients were exposed to statins on admission, of which 340 (57.2%) were male. The mean age was higher in statin users compared to non-users [64.9 ± 13.4 vs. 45.5 ± 16.6 years, p <0.001]. The average treatment effect of statin use on COVID-19-related mortality was RR = 1.00 (95% CI: 0.99–1.01, p = 0.928), while its effect on severe COVID-19 infection was RR = 1.18 (95% CI: 1.11–1.27, p <0.001). CONCLUSION: Statin use was not associated with altered mortality, but with an 18% increased risk of severe COVID-19 infection.
Search related documents:
Co phrase search for related documents- ace inhibitor and logistic regression: 1, 2, 3, 4, 5, 6, 7
- ace inhibitor and low density: 1, 2
- ace inhibitor and low density cholesterol: 1, 2
- ace inhibitor and low density cholesterol lipoprotein: 1, 2
- additional study and adjuvant therapy: 1, 2
- additional study and adjuvant vaccine: 1
- additional study and admission death: 1, 2
- additional study and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- additional study and low density: 1
- additional study and low density cholesterol: 1
- additional study and low density cholesterol lipoprotein: 1
- adjuvant therapy and admission death: 1
- adjuvant therapy and liver function: 1, 2
- adjuvant therapy and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- adjuvant therapy and low density: 1
- admission death and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- admission death and low density: 1, 2, 3, 4, 5
- admission death and low density cholesterol: 1, 2, 3, 4, 5
- admission death and low density cholesterol lipoprotein: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date